{"id":"anthrax-immune-globulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108699","moleculeType":"Unknown"},"_dailymed":{"setId":"97cc9a89-6fe0-424e-82d1-0cf9d19444db","title":"ANTHRASIL (ANTHRAX IMMUNE GLOBULIN (HUMAN)) LIQUID [EMERGENT BIOSOLUTIONS CANADA INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This polyclonal immunoglobulin product contains human antibodies directed against anthrax protective antigen (PA) and lethal factor (LF), the key virulence factors of Bacillus anthracis. When administered, these antibodies bind to and neutralize anthrax toxins, preventing their cellular effects and facilitating bacterial clearance. It is used as an adjunctive therapy alongside antibiotics in inhalational anthrax infection.","oneSentence":"Anthrax Immune Globulin provides passive immunization by supplying antibodies that neutralize anthrax toxins and enhance clearance of Bacillus anthracis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:44.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inhalational anthrax (adjunctive therapy with antibiotics)"}]},"trialDetails":[{"nctId":"NCT05997264","phase":"PHASE2","title":"Anthrax AV7909 Boost Evaluation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2023-12-05","conditions":"Anthrax","enrollment":220},{"nctId":"NCT03569553","phase":"","title":"A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2027-05-30","conditions":"Inhalational Anthrax","enrollment":100},{"nctId":"NCT03569514","phase":"","title":"Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax","status":"NOT_YET_RECRUITING","sponsor":"Emergent BioSolutions","startDate":"2026-11-30","conditions":"Anthrax","enrollment":10},{"nctId":"NCT00845650","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2009-02","conditions":"Anthrax","enrollment":129},{"nctId":"NCT00448253","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2007-07","conditions":"Symptoms of Inhalational Anthrax","enrollment":92},{"nctId":"NCT01932242","phase":"PHASE1","title":"Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers","status":"COMPLETED","sponsor":"Elusys Therapeutics","startDate":"2013-07-23","conditions":"Inhalational Anthrax","enrollment":70},{"nctId":"NCT01929226","phase":"PHASE1","title":"Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers","status":"COMPLETED","sponsor":"Elusys Therapeutics","startDate":"2013-07-09","conditions":"Inhalational Anthrax","enrollment":280},{"nctId":"NCT00138411","phase":"PHASE1","title":"Monoclonal Antibody for Treatment of Inhalation Anthrax","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Bacillus Anthracis (Anthrax)","enrollment":36},{"nctId":"NCT00031291","phase":"","title":"Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-02","conditions":"Anthrax","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anthrax Immune Globulin","genericName":"Anthrax Immune Globulin","companyName":"National Institutes of Health Clinical Center (CC)","companyId":"national-institutes-of-health-clinical-center-cc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anthrax Immune Globulin provides passive immunization by supplying antibodies that neutralize anthrax toxins and enhance clearance of Bacillus anthracis. Used for Inhalational anthrax (adjunctive therapy with antibiotics).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}